Medical News

RSS

Extreme summer heat in Montreal may have effect on early-term deliveries

When temperatures reach 32-C or higher over a period of four to seven days, the risk of early-term delivery is 27% higher than on typical summer days, according to a study led by Nathalie Auger of the University of Montreal's Department of Social and Preventive Medicine. The study involved data from 300,000 births that took place in Montreal between 1981 to 2010 with summer temperatures recorded by Environment Canada during this period. Auger is also affiliated with the university's CHUM Superhospital Research Centre.

1 Apr 2014

Retinoic acid helps turn pre-cancer cells back to normal healthy breast cells

A derivative of vitamin A, known as retinoic acid, found abundantly in sweet potato and carrots, helps turn pre-cancer cells back to normal healthy breast cells, according to research published this month in the International Journal of Oncology. The research could help explain why some clinical studies have been unable to see a benefit of vitamin A on cancer: the vitamin doesn't appear to change the course of full-blown cancer, only pre-cancerous cells, and only works at a very narrow dose.

31 Mar 2014

TUFS tool useful for assessing storage symptoms in OAB

The total urgency and frequency score is a useful tool for assessing changes in major storage symptoms in patients with overactive bladder, researchers believe.

31 Mar 2014

Simple tool may aid insomnia diagnoses

UK researchers have developed a “brief but versatile” tool, based on standard diagnostic criteria, to screen patients for insomnia disorder.

31 Mar 2014

S. pneumoniae is commonest cause of paediatric CAP

Streptococcus pneumoniae is the predominant cause of community-acquired pneumonia among children in Belgium, with non-vaccine serotypes accounting for the majority of cases, a Belgian study shows.

31 Mar 2014

Solid-dominant lung cancer histology no barrier to segmentectomy

Complete resection with segmentectomy is as effective as lobectomy for patients with solid-dominant clinical stage IA lung adenocarcinoma, Japanese study findings suggest.

31 Mar 2014

Lobar offers no survival advantage over sublobar resections in NSCLC

Patients do not survive significantly longer after lobectomy for non-small-cell lung cancer than after wedge resection or segmentectomy, indicate US study results.

31 Mar 2014

Rigorous blood pressure control could halve recurrent stroke risk

Ensuring that the blood pressure of stroke survivors is controlled at least three-quarters of the time may halve their risk of a recurrence, shows a secondary analysis of the VISP trial.

31 Mar 2014

Geographical variation in antipsychotic efficacy not ruled out

An individual patient data meta-analysis fails to exclude the possibility that atypical antipsychotics work better in patients from some parts of the world than others.

31 Mar 2014

Antimuscarinics plus α-blockers ‘recommended for male LUTS’

Antimuscarinics “could and should” be used in the pharmacological treatment of men with lower urinary tract symptoms caused by benign prostatic hyperplasia or bladder outlet obstruction, say the authors of a meta-analysis published in Urology.

31 Mar 2014

Cognitive deficits in bipolar patients ‘not homogenous’

Patients with bipolar disorder can be separated into three groups based on their cognitive performance, a study suggests.

31 Mar 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Halozyme meets primary endpoint in Hylenex CONSISTENT 1 trial

Halozyme Therapeutics, Inc. today announced that the primary endpoint of non-inferiority of A1C levels at six months was met for the CONSISTENT 1 trial. The trial is evaluating Hylenex® recombinant and a new formulation of Hylenex currently under U.S Food and Drug Administration (FDA) review, when used as pretreatment of the insulin infusion site in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion (CSII) in comparison to no pre-treatment.

31 Mar 2014

Americans' experience with health law depends on where they live

Some states that embraced the law, like Oregon, have had difficulty enrolling residents because of glitch-ridden online marketplaces, while others like New Hampshire have seen unexpectedly strong enrollments despite prevailing critical views.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

BioLight seeks FDA IND approval for subconjunctival Latanoprost controlled release insert Phase I/IIa study

BioLight Israeli Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announces that ViSci, its wholly owned subsidiary, has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a Phase I/IIa clinical study with its subconjunctival Latanoprost controlled release insert for the treatment of glaucoma.

31 Mar 2014

Artists benefit from health law, but rural residents may pay more

Self-employed Americans such as artists stand to gain under the health law, but rural residents may pay more for coverage because of the higher costs of delivering care in a sparsely populated area and the disproportionate number of older people. Other media outlets offer advice for consumers trying to make sense of the law.

31 Mar 2014

Cellulose nanofiber paper filter removes virus particles with high efficiency

Researchers at the Division of Nanotechnology and Functional Materials, Uppsala University have developed a paper filter, which can remove virus particles with the efficiency matching that of the best industrial virus filters. The paper filter consists of 100 percent high purity cellulose nanofibers, directly derived from nature.

31 Mar 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014